Practice Locations

Children's Hospital Colorado Anschutz Medical Campus
Aurora
13123 East 16th Ave Aurora, CO 80045

720-777-1234

Elizabeth McFarland, MD

Pediatric Infectious Diseases

Board Certified

Locations

Practice Locations

Children's Hospital Colorado Anschutz Medical Campus
13123 East 16th Ave
Aurora, CO 80045

720-777-1234

Get directions

Provider Expertise

Clinical Interest for Patients

I am interested in pediatric infectious diseases, particularly pediatric and perinatal HIV Infection.


Specialties

  • Pediatric Infectious Diseases ( 1992 , 2008 )
  • Pediatrics ( 1990 , 2014 )

Conditions & Treatments

  • Kawasaki Disease

  • Immune System

    AIDS, AIDS / HIV Disease, AIDS Immunization

  • Symptoms and Manifestations

    Fever

  • Infections

    Bacterial, Fungal, Influenza, Pneumonia, Viral

Education & Training

Medical Schools

MD, Duke University School of Medicine (1985)


Undergraduate Schools

BS, Northwestern University (IL) (1981)


Internships

University of Colorado (University Hospital) Program (1986)


Residency Program

University of Colorado (University Hospital) Program (1988)


Fellowships

University of Colorado (University Hospital) Program (1992)

Professional Memberships

Pediatric Infectious Disease Society, Member


Research & Grants

Research Interests for Patients

Dr. McFarland’s primary areas of research interest are HIV passive and active immunization and immune-based HIV therapy, the role of HIV-specific cell-mediated immunity in HIV pathogenesis and response to therapy and RSV vaccine clinical trials. She is leading clinical research protocols focused on HIV-1 specific broadly neutralizing monoclonal antibody (bNAb) for infants exposed to HIV-1 and for infant early antiretroviral treatment. She serves as Vice Chair of the International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) HIV Cure Committee, as member of the Pediatric Advisory Committee to the HIV Vaccine Trials Network (HVTN), as a co-investigator for the Pediatrics Adolescent Virus Eradication (PAVE) Martin Delaney Collaboratory, site principal investigator for the multicenter Pediatric AIDS/HIV Cohort Study (PHACS), and member of the PHACS Nutrition, Metabolic, Growth Working Group. She has served on the AIDS Research Advisory Council, Division of AIDS (DIADS) at the National Institutes of Health (NIH). Dr. McFarland has had continuous NIH and HRSA funding since 1995.

information for referring providers

Referral Contact Phone

(720) 777-6981

Clinical Interests for Referring Providers

I am interested in pediatric infectious diseases, particularly pediatric and perinatal HIV Infection.

Research Interest for Referring Providers

Dr. McFarland’s primary areas of research interest are HIV passive and active immunization and immune-based HIV therapy, the role of HIV-specific cell-mediated immunity in HIV pathogenesis and response to therapy and RSV vaccine clinical trials. She is leading clinical research protocols focused on HIV-1 specific broadly neutralizing monoclonal antibody (bNAb) for infants exposed to HIV-1 and for infant early antiretroviral treatment. She serves as Vice Chair of the International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) HIV Cure Committee, as member of the Pediatric Advisory Committee to the HIV Vaccine Trials Network (HVTN), as a co-investigator for the Pediatrics Adolescent Virus Eradication (PAVE) Martin Delaney Collaboratory, site principal investigator for the multicenter Pediatric AIDS/HIV Cohort Study (PHACS), and member of the PHACS Nutrition, Metabolic, Growth Working Group. She has served on the AIDS Research Advisory Council, Division of AIDS (DIADS) at the National Institutes of Health (NIH). Dr. McFarland has had continuous NIH and HRSA funding since 1995.